Leadership

Our team brings together pioneers in NK cells and leaders in cell therapy product development.


Founded by pioneers in NK cell engineering and biology and steered by a leadership team with deep cell therapy experience, Catamaran has assembled the collective expertise to develop transformative cell therapies to treat cancer.

We have a purpose-built team of scientists and drug developers who have the specific know-how and proven track records needed to design, develop and manufacture novel CAR-NK cell therapies. We have come together at Catamaran to discover and develop CAR-NK cell therapies that will change the lives of cancer patients.

The Catamaran leadership team has deep expertise building cell therapy platforms and rapidly advancing product pipelines. Each member of our team has worked in the emerging cell therapy field with first-hand experience discovering and developing cell therapy products. From NK cell biology and synthetic biology through translation to the clinic and product manufacturing, we bring our unique insights and passion to develop improved cell therapies for patients.

Alvin Shih, MD, MBA

Alvin Shih, MD, MBA

CEO

Vipin Suri, PhD, MBA

Vipin Suri, PhD, MBA

Chief Scientific Officer

Dave Sutherland

Dave Sutherland

Vice President, Finance and Operations

Dominic Picarella, PhD

Dominic Picarella, PhD

Senior Director, In Vivo Pharmacology

Joseph Gold, PhD

Joseph Gold, PhD

Vice President, Technical Operations and Manufacturing